

Atezolizumab Biosimilar - Research Grade ICH4018

Product Information

Catalog Number:	ICH4018
Product:	Low endotoxin, biosimilar antibody
Target:	PD-L1
Isotype:	IgG1 kappa
Other names:	Programmed cell death 1 ligand 1, Cd274, PDCD1 ligand 1, Programmed death ligand 1, B7 homolog 1, B7-H1, B7h1, Pcd1l1, Pdcd1lg1, Pdl1, PDL-1
Host:	Humanized
Species Reactivity:	Human
Specificity:	Detects human PDL-1. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Atezolizumab.
Purification method:	This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Concentration:	1.0 - 5.0 mg/ml
Formulation:	Phosphate buffered saline (PBS) pH 7.2, with no carrier protein, potassium or preservatives added. BSA and Azide free.
Purity:	>95% by SDS-PAGE and HPLC
Endotoxin:	≤ 0.75 EU/mg as determined by the LAL method
Storage:	Stable for at least one week when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Background:

Atezolizumab biosimilar is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab biosimilar is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.